Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| PGF-H52G3 | Human | Human PLGF / PGF (19-149) Protein, GST Tag |  |
||
| PGF-H5255 | Human | Human PLGF / PGF (19-221) Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H5256 | Human | Human PLGF / PGF (19-149) Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H52H5 | Human | Human PLGF / PGF (19-149) Protein, His Tag (MALS verified) |  |
|
|
| PGF-M52H0 | Mouse | Mouse PLGF / PGF Protein, His Tag |  |
|
|
| PGF-R52H0 | Rhesus macaque | Rhesus macaque PLGF / PGF Protein, His Tag |  |
|
|
| PGF-H5229 | Human | Human PLGF / PGF Protein, His Tag |  |
|
|
Immobilized Human VEGF R1, His Tag (Cat. No. VE1-H5220) at 2 μg/mL (100 μL/well) can bind Human PLGF (19-149), Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.6-5 ng/mL (QC tested).
The purity of Human PLGF (19-221), Fc Tag (Cat. No. PGF-H5255) was more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ziv-aflibercept | AVE-0005; BAY-865321 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | Zaltrap | Japan | Colorectal Neoplasms | Sanofi | 2012-08-03 | Solid tumours; Ovarian Neoplasms; Lung Diseases; Ascites; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Lung Neoplasms; Neoplasm Metastasis | Details |
| Aflibercept | BAY-865321; BAT-86-5321 | Approved | Regeneron Pharmaceuticals Inc, Bayer Ag | Eylea | Mainland China | Macular Degeneration; Macular Edema | Bayer Australia Ltd | 2011-11-18 | Wet Macular Degeneration; Retinopathy of Prematurity; Diabetic Retinopathy; Diabetes Mellitus; Neoplasm Metastasis; Macular Degeneration; Retinal Vein Occlusion; Retinal Degeneration; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetic macular oedema; Prostatic Neoplasms; Retinal Diseases; Myopia, Degenerative; Neoplasms; Glaucoma, Neovascular; Diabetes Mellitus, Type 2; Macular Edema | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Aflibercept biosimilar (CinnaGen)(阿柏西普生物类似药（CinnaGen）) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Aflibercept biosimilar (Amgen) | Phase 2 Clinical | Amgen Inc | Macular Degeneration | Details | |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15 | Phase 3 Clinical | Samsung Bioepis | Macular Degeneration | Details |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Phase 3 Clinical | Mylan, Momenta | Diabetic macular oedema | Details |
| Aflibercept/Nesvacumab | REGN 910-3 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Diabetic macular oedema; Macular Degeneration | Details |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Diabetic macular oedema; Macular Degeneration | Details |
| Aflibercept biosimilar (Mabwell) | 9MW0813 | Phase 1 Clinical | Diabetic macular oedema | Details | |
| Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Diabetic macular oedema; Macular Degeneration | Details |
| Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd | Wet Macular Degeneration; Colorectal Neoplasms; Macular Degeneration | Details |
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Macular Degeneration | Details |
| Anti-placental growth factor monoclonal antibody | αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 | Phase 2 Clinical | Thrombogenics, Bioinvent International | Retinal Telangiectasis; Medulloblastoma; Solid tumours; Ovarian Neoplasms; Macular Edema; Glioblastoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Diabetic Retinopathy; Macular Degeneration; Diabetes Mellitus | Details |
| Aflibercept Biosimilar (Clover Biopharmaceuticals) | SCB-420 | Phase 1 Clinical | Sichuan Sanyecao Bio-Pharmaceutical Co Ltd | Diabetic macular oedema; Macular Degeneration | Details |
| CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion | Diabetic macular oedema | Details |
| FYB-203 | FYB-203 | Phase 3 Clinical | Formycon | Macular Degeneration | Details |
This web search service is supported by Google Inc.
A-Z